{
    "clinical_study": {
        "@rank": "72408", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Combining chemotherapy with autologous bone marrow\n      transplantation may help the body kill more tumor cells.\n\n      PURPOSE: Phase II trial to study the effects of high doses of carboplatin, etoposide, and\n      cyclophosphamide followed by autologous bone marrow transplantation in patients with\n      relapsed or refractory germ cell cancer and other chemotherapy-sensitive solid tumors."
        }, 
        "brief_title": "Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer", 
        "completion_date": {
            "#text": "August 2007", 
            "@type": "Actual"
        }, 
        "condition": [
            "Extragonadal Germ Cell Tumor", 
            "Ovarian Cancer", 
            "Testicular Germ Cell Tumor", 
            "Unspecified Adult Solid Tumor, Protocol Specific"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Ovarian Neoplasms", 
                "Neoplasms, Germ Cell and Embryonal"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Investigate the response rate, duration of response, survival, time to marrow\n           reconstitution, and toxicity of two successive cycles of high dose carboplatin,\n           etoposide, and cyclophosphamide chemotherapy and ABMT in patients with relapsed and\n           refractory germ cell cancer or other chemotherapy-sensitive solid tumors.\n\n        -  Further define the pretransplant characteristics of patients and their disease that\n           might influence the outcome of this therapy.\n\n      OUTLINE: Patients receive carboplatin and etoposide for 5 days and cyclophosphamide for 2\n      days prior to ABMT.\n\n      At day 60 following ABMT, if the patient has a complete response (CR) or partial response\n      (PR) and nonhematologic toxicity is no greater than grade 2, a second ABMT course is given\n      when hematologic parameters and other criteria are acceptable. If there is no CR or PR\n      and/or nonhematologic toxicity exceeds grade 2, a second ABMT is not given.\n\n      After ABMT patients are followed until disease progression or death.\n\n      PROJECTED ACCRUAL: Ten patients will be accrued for this pilot study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed, measurable germ cell cancer relapsed or refractory after\n             frontline therapy with cisplatin and etoposide-containing chemotherapy\n\n          -  Other chemotherapy-sensitive solid tumors eligible (as of 06/11/97)\n\n          -  Possibility of residual mass representing benign teratoma must be excluded\n\n          -  Elevated serum tumor markers only are acceptable if possibilities of false-positive\n             serum tumor markers or sanctuary disease have been excluded\n\n          -  Also eligible after two to four cycles of conventional dose salvage chemotherapy,\n             regardless of response\n\n          -  No CNS or bone marrow involvement\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  Greater than 2 months\n\n        Hematopoietic:\n\n          -  Platelet count at least 100,000/mm3\n\n          -  Neutrophil count at least 1,500/mm3\n\n        Hepatic:\n\n          -  Bilirubin, alkaline phosphatase, SGOT, and SGPT less than 3 times upper limit of\n             normal, unless due to disease\n\n        Renal:\n\n          -  Creatinine less than 1.5 times upper limit of normal\n\n          -  Creatinine clearance at least 60 ml/min\n\n        Cardiovascular:\n\n          -  Ventricular ejection fraction at least 45%\n\n          -  No uncontrolled or severe cardiovascular disease including recent myocardial\n             infarction, congestive heart failure, angina, life-threatening arrhythmia, or\n             hypertension\n\n        Pulmonary:\n\n          -  DLCO and spirometry greater than 50% of predicted\n\n        Other:\n\n          -  Not HIV positive\n\n          -  No active peptic ulcer\n\n          -  No uncontrolled diabetes mellitus\n\n          -  No active infection\n\n          -  No previous or concomitant malignancy other than curatively treated basal or squamous\n             cell carcinoma of the skin\n\n          -  Not HBsAG positive\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  No prior high-dose carboplatin, etoposide, or cyclophosphamide\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  Not specified\n\n        Surgery:\n\n          -  Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "11", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002943", 
            "org_study_id": "CDR0000065392", 
            "secondary_id": [
                "CCCWFU-95193", 
                "NCI-G97-1146"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "etoposide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "autologous bone marrow transplantation", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Etoposide phosphate", 
                "Etoposide", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "stage III malignant testicular germ cell tumor", 
            "recurrent malignant testicular germ cell tumor", 
            "unspecified adult solid tumor, protocol specific", 
            "stage III ovarian germ cell tumor", 
            "stage IV ovarian germ cell tumor", 
            "recurrent ovarian germ cell tumor", 
            "extragonadal germ cell tumor"
        ], 
        "lastchanged_date": "July 12, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/CCCWFU-95193"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Winston-Salem", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27157-1082"
                }, 
                "name": "Comprehensive Cancer Center at Wake Forest University"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "High Dose Carboplatin, Etoposide, Cyclophosphamide and Autologous Bone Marrow Transplantation for Relapsed and Refractory Germ Cell Cancer: A Phase II Pilot Study", 
        "overall_official": {
            "affiliation": "Comprehensive Cancer Center of Wake Forest University", 
            "last_name": "David D. Hurd, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "To investigate the response rate High Dose Carboplatin, Etoposide, Cyclophosphamide and Autologous Transplantation", 
            "safety_issue": "No", 
            "time_frame": "45 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002943"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "evaluate toxicity of High Dose Carboplatin, Etoposide, Cyclophosphamide and Autologous Transplantation", 
            "time_frame": "45 days"
        }, 
        "source": "Comprehensive Cancer Center of Wake Forest University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Comprehensive Cancer Center of Wake Forest University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 1993", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }, 
    "geocoordinates": {
        "Comprehensive Cancer Center at Wake Forest University": "36.1 -80.244"
    }
}